Page 25 - Mark Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Two of the three research studies -- led by Jacqueline Douglass, M.D., Ph.D. candidate at the Johns Hopkins University School of Medicine and Emily Han-Chung Hsiue, M.D., Ph.D., postdoctoral fellow at Johns Hopkins--report on a precision medicine immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented as antigens on the cancer cell surface. Although common across cancer types, p53 mutations have not been successfully targeted with drugs. Genetic alterations in tumor suppressor genes often resulted in their functional inactivation. "Tradition...

 E-Mail IMAGE: Cancer evades the immune system by "feeding " the T cells that protect the tumor and "starving " the T cells that would attack. view more  Credit: UPMC, created with BioRender.com PITTSBURGH, Feb. 15, 2021 - A paper published today in Nature shows how chemicals in the areas surrounding tumors--known as the tumor microenvironment--subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy. The study was conducted by a team of scientists at UPMC Hillman Cancer Center and the University of...

 E-Mail The Mark Foundation for Cancer Research (MFCR) has awarded seven grants to promising early-career investigators for projects aimed at addressing unmet needs in cancer research. The Emerging Leader Award program empowers scientists to take on innovative, high-risk/high-reward projects that have significant potential to improve outcomes for cancer patients. The 2021 MFCR Emerging Leaders are pursuing important studies in areas of basic, translational, and clinical cancer research, including probing the function of cancer stem cells in brain cancer, discerning the unique molecular featu...

The toll from COVID is immense, with more than 90 million people affected and nearly 2 million dead across the world. Yet these numbers don’t tell the full story. The pandemic’s collateral damage in other diseases, like cancer, is rising and will only make itself fully felt in the next few years.

 E-Mail The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2021 recipients of the Damon Runyon-Rachleff Innovation Award. Five initial grants of $400,000 over two years were awarded to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer. Each project will have the opportunity for up to two additional years of funding (four years total for $800,000). This year, "Stage 2" continuation support was granted to two awardees who demonstrat...